LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Completed · Phase 3 · Has a placebo group

Conditions studied: COVID-19

In brief

This study looks at the safety and effectiveness of LY3819253 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either LY3819253 plus current standard of care (SOC), or with placebo plus current SOC. This is ACTIV-3/TICO Treatment Trial H1.

Key facts

Study ID
NCT05780268
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
People needed
314
Starts
2020-08-05
Expected to finish
2021-02-01
Last updated by the study team
2023-12-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.